Avanir To File Neurodex NDA For Pseudobulbar Affect By End Of 2004

Firm will request priority review for the dextromethorphan/quinidine combination. A broad indication covering PBA (uncontrollable laughing/crying) in a range of neurological diseases is expected based on an agreement with FDA.